Arch Therapeutics, Inc.
ARTH · OTC
9/30/2023 | 9/30/2022 | 9/30/2021 | 9/30/2020 | |
|---|---|---|---|---|
| Revenue | $0 | $0 | $0 | $0 |
| % Growth | 383.8% | 35.3% | – | – |
| Cost of Goods Sold | $0 | $0 | $0 | $0 |
| Gross Profit | -$0 | -$0 | -$0 | -$0 |
| % Margin | -3.2% | -229% | -127.3% | – |
| R&D Expenses | $1 | $1 | $1 | $2 |
| G&A Expenses | $4 | $5 | $5 | $4 |
| SG&A Expenses | $4 | $5 | $5 | $4 |
| Sales & Mktg Exp. | $0 | $0 | $0 | $0 |
| Other Operating Expenses | $0 | $0 | $0 | $0 |
| Operating Expenses | $5 | $6 | $6 | $5 |
| Operating Income | -$5 | -$6 | -$6 | -$5 |
| % Margin | -6,661.7% | -36,473.3% | -55,141.6% | – |
| Other Income/Exp. Net | -$2 | $0 | $0 | $1 |
| Pre-Tax Income | -$7 | -$5 | -$6 | -$5 |
| Tax Expense | $0 | $0 | $0 | $0 |
| Net Income | -$7 | -$4 | -$7 | -$4 |
| % Margin | -9,221.4% | -27,318.3% | -56,802.8% | – |
| EPS | -2.27 | -3.56 | -5.97 | -4.27 |
| % Growth | 36.2% | 40.4% | -39.8% | – |
| EPS Diluted | -2.27 | -3.56 | -5.97 | -4.27 |
| Weighted Avg Shares Out | 3 | 1 | 1 | 1 |
| Weighted Avg Shares Out Dil | 3 | 1 | 1 | 1 |
| Supplemental Information | – | – | – | – |
| Interest Income | $0 | $0 | $0 | $0 |
| Interest Expense | $3 | $1 | $0 | $0 |
| Depreciation & Amortization | $0 | $0 | $0 | $0 |
| EBITDA | -$4 | -$5 | -$6 | -$5 |
| % Margin | -5,129.6% | -30,064% | -52,636.1% | – |